Benzinga | Sep 7, 2021 07:56AM EDT

RedHill Unveils New Movantik Data For Opioid-Induced Constipation

* RedHill Biopharma Ltd (NASDAQ:RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses.

* The three analyses included pooled data from two Phase 3 studies involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 446 patients in the placebo arms.

* It presented the data at the PAINWeek 2021.

* New data demonstrated rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged above 65 years and across both low and high-dose opioid therapy.

* In patients aged 65 years and above, Movantik achieved significantly better response rates vs. placebo, with rapid onset of action and a higher proportion of subjects achieving spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM) over the first 48 hours of treatment.

* Additional data also shows that naloxegol delivers similar rapid and sustained symptom improvement for patients, irrespective of the opioid dose.

* Related Content: Cantor Sees 'Compelling Investment Opportunity' In This Biopharma.

* Price Action: RDHL shares closed 5.19% lower at $9.49 on Friday.